Limited-sampling strategies for anti-infective agents: Systematic review

Canadian Journal of Hospital Pharmacy

Volumn 62, Issue 5, 2009, Pages 392-401

  Sprague, Denise A ^a   Ensom, Mary H H ^b  

^a KELOWNA GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti infectives; Limited sampling strategy; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MEROPENEM; NELFINAVIR; NEVIRAPINE; PYRAZINAMIDE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; VANCOMYCIN; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONTINUOUS INFUSION; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; EMBASE; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MEDLINE; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RETINITIS; SEPSIS; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULOSIS; VALIDATION STUDY;

EID: 70350706463     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: 10.4212/cjhp.v62i5.827     Document Type: Article

References (48)

1. Ensom MHH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34(4):265-279.
2. Slavik RS, Jewesson PJ. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 2003;42(9):793-817.
3. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis and application of population pharmacokinetic studies. Ann Pharmacother 2004;38(12):2136-2144. (Pubitemid 40169387)
4. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007;46(3):221-234.
5. Ting LSL, Villeneuve E, Ensom MHH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006;28(3):419-430. (Pubitemid 44314932)
6. Loh GW, Ting LSL, Ensom MHH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet 2007;46(6):471-494.
7. Pattar R, Ensom MHH. Utility of limited sampling strategies for anticancer agents in the clinical arena: a systematic review. Curr Cancer Ther Rev 2009;5(1):45-66.
8. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9(4):503-512.
9. US Preventive Services Task Force, editors. Guide to preventive services: report of the US Preventive Services Task Force. 2nd ed. Baltimore (MD): Williams & Wilkins; 1996.
10. Tod M, Padoin C, Louchahi K, Moreau-Tod B, Petitjean O, Perret G. Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification. J Pharmacokinet Biopharm 1994;22(2):129-146.
11. Suarez-Kurtz G, Ribeiro FM, Vicente FL, Struchiner CJ. Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters. Antimcrob Agents Chemother 2001;45(11):3029-3036.
12. Suarez-Kurtz G, Bozza FA, Vicente FL, Ponte CG, Stuchiner CJ. Limited-sampling strategy models for itraconazole and hydroxyitraconazole based on data from a bioequivalence study. Antimicrob Agents Chemother 1999;43(1):134-140. (Pubitemid 29069212)
13. Uematsu T. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. Int J Clin Pharmacol Ther Toxicol 1993;31(12):606-610.
14. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 1988;44(2):232-238. (Pubitemid 18197419)
15. Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutroprnic cancer patients. Clin Pharmacol Ther 1989;45(6):635-641. (Pubitemid 19184175)
16. Rodvold KA, Rotschafer JC, Gilliland SS, Guay DR, Vance-Bryan K. Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies. Ther Drug Monit 1994;16(1):37-41.
17. Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005;49(7):2760-2766.
18. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, et al.; Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther 2003;74(6):569-580.
19. Terziivanov D, Atanasova I, Dimitrova V. Population pharmacokinetics of ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm - a retrospective study. Int J Clin Pharmacol Ther 1998;36(7):376-382.
20. Kisor DF, Watling SM, Zarowitz BJ, Jelliffe RW. Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. Clin Pharmacokinet 1992;23(1):62-68.
21. Noormohamed SE, Henry WK, Rhame FS, Balfour HH Jr, Fletcher CV. Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother 1995;39(12):2792-2797.
22. Yuen GJ, Drusano GL, Forrest A, Plaisance K, Caplan ES. Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1989;46(4):451-457.
23. Amsden GW, Ballow CH. Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokinetics. Pharmacotherapy 1996;16(5):937-941.
24. Mueller BU, Pizzo PA, Farley M, Husson RM, Goldsmith J, Kovacs A, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr 1994;125(1):142-146.
25. Burger DM, Meenhorst PL, ten Napel CHH, Mulder JW, Henrichs JH, Frissen PHJ, et al. Limited sampling models for the antiretroviral agent didanosine. Eur J Pharm Sci 1995;3(1):7-13.
26. Burger DM, Van Warmerdam LJC, Rosing H, et al. Development and validation of limited-sampling models for the antiretroviral agent zidovudine. Drug Invest 1993;6:189-197. (Pubitemid 23294327)
27. Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Hoetelmans RM, Lange JM, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit 2001;23(6):606-611.
28. Payen S, Serreau R, Munck A, Aujard Y, Aigrain Y, Bressolle F, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother 2003;47(10):3170- 3178.
29. López-Cortés LF, Ruiz-Valderas R, Marin-Niebla A, Pascual-Carrasco R, Rodriguez-Diez M, et al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr 2005;39(5):551-556. (Pubitemid 41098469)
30. Regazzi MB, Tinelli C, Villani P, Cusato M, De Silvestri A, Briganti E, et al. Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir. Ther Drug Monit 2005;27(5):571-575.
31. Burstein AH, Gal P, Forrest A. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Ann Pharmacother 1997;31(9):980-983. (Pubitemid 27390951)
32. Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992;165(1):99-104.
33. Mueller BU, Lewis LL, Yuen GJ, Farley M, Keller A, Church JA, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1998;42(12):3187-3192.
34. Alexander CS, Montaner JS, Asselin JJ, Ting L, McNabb K, Harris M, et al. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection. Ther Drug Monit 2004;26(6):516-523.
35. Vinks AATTM, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 1996;40(5):1091-1097.
36. Dickinson L, Back D, Pozniak A, Khoo S, Boffito M. Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. Ther Drug Monit 2007;29(3):361-367. (Pubitemid 47262268)
37. Preston SL, Drusano GL. Nonparametric expectation maximization population modeling of ganciclovir. J Clin Pharmacol 1996;36(4):301-310.
38. Kashuba AMD, Ballow CH, Forrest A. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob Agents Chemother 1996;40(8):1860-1865. (Pubitemid 26277806)
39. Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, et al. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. J Antimicrob Chemother 2000;45(3):343-347. (Pubitemid 30139243)
40. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Remmel RP, et al. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis 2004;38(4):556-564. (Pubitemid 38250967)
41. Ariano RE, Zelenitsky SA, Nyhlén A, Sitar DS. An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics. J Clin Pharmacol 2005;45(7):832-835. (Pubitemid 40875335)
42. Andrés I, López R, Pou L, Piñol F, Pascual C. Vancomycin monitoring: one or two serum levels? Ther Drug Monit 1997;19(6):614-619.
43. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37(5):1065-1072.
44. Chatelut E, Rostaing L, Grégoire N, Payen JL, Pujol A, Izopet J, et al. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 1999;47(4):365-371. (Pubitemid 29161267)
45. Dahri K, Ensom MHH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet 2007;46(2):109-132.
46. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006;28(3):468-473. (Pubitemid 44314939)
47. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington (DC): Department of Health and Human Services; 2008 [cited 2008 Mar 20]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
48. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42 Suppl 1:S35-S39.